Is Inhibikase Therapeutics Inc (IKT) a Bad Choice in Biotechnology Wednesday?

A rating of 35 puts Inhibikase Therapeutics Inc (IKT) near the middle of the Biotechnology industry according to InvestorsObserver. Inhibikase Therapeutics Inc’s score of 35 means it scores higher than 35% of stocks in the industry. Inhibikase Therapeutics Inc also received an overall rating of 36, putting it above 36% of all stocks. Biotechnology is ranked 67 out of the 148 industries.

IKT has an Overall Score of 36. Find out what this means to you and get the rest of the rankings on IKT!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 36 would rank higher than 36 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What’s Happening With Inhibikase Therapeutics Inc Stock Today?

Inhibikase Therapeutics Inc (IKT) stock has gained 18.81% while the S&P 500 has fallen -0.71% as of 3:25 PM on Wednesday, Sep 20. IKT has risen $0.19 from the previous closing price of $1.01 on volume of 260,105 shares. Over the past year the S&P 500 has gained 14.43% while IKT has fallen -77.57%. IKT lost -$4.17 per share the over the last 12 months.

Click Here to get the full Stock Report for Inhibikase Therapeutics Inc stock.